The effect of XXXX on muscle cramps during hemodialysis: A double-blind clinical trial.

@entity1 @entity21665 @entity2682 @entity454
UNASSIGNED: @entity21665 ( @entity21665 ) are a common complication during hemodialysis (HD) sessions. A number of pharmacologic agents have been evaluated to prevent and or diminish @entity21665 ; however, none of them has an established role. To the best of our knowledge, this is the first study to evaluate the possible effect of @entity2682 on @entity21665 . In a double-blinded clinical trial, we compared the possible effect of @entity2682 with a placebo in prevention and or diminishing episodes of @entity21665 in HD @entity1 who had experienced frequent intradialytic muscle cramps. At first, placebo was given before each dialysis session for four weeks and then, after a two-week washout period, 300 mg of @entity2682 was given before each dialysis session for four weeks to verify the effect of @entity2682 on @entity21665 . Overall, 15 @entity1 (seven @entity1 and eight @entity1 ; mean age, 52.02 years) with frequent intradialytic muscle cramps were enrolled in the study. The incidence of symptomatic muscle cramp decreased in the @entity2682 group compared with the placebo group, with a significant difference between them (P = 0.001). The intensity of muscle cramps also decreased in the @entity2682 group (P = 0.001). There was no significant association between @entity21665 in male and female @entity1 (P = 0. 397), mean age of HD @entity1 (P = 0.226) and cause of @entity454 (P = 0.551). According to the results of our study, @entity2682 prescription before each HD session significantly reduced the frequency and the intensity of muscle cramps during HD without any major side-effects.
